Lithium as a disease-modifying agent for prion diseases.

Area of Science:

• Neuroscience
• Pharmacology
• Biomedical Engineering

Background:

• Prion diseases are currently incurable, necessitating symptomatic treatment strategies.
• Lithium is recognized for its neuroprotective properties, but chronic use can lead to toxicity.
• Developing effective drug delivery systems is crucial for managing neurodegenerative conditions.

Purpose of the Study:

• To evaluate the efficacy of lithium delivered via a water-in-oil microemulsion (Aonys®) in a preclinical model of prion disease.
• To determine if low-dose lithium administration using this novel system can mitigate prion disease progression and associated neuropathology.
• To compare the therapeutic effects of low-dose microemulsion-delivered lithium with traditional high-dose administration.

Main Methods:

• C57BL/6J mice were intracranially inoculated with ME7 prion-infected brain homogenates.
• Treatment with lithium commenced at 90 days post-inoculation until the animals' death.
• Lithium was administered at conventional doses (16 mg/kg/day) via gavage and at low doses (40 or 160 µg/kg/day) using the Aonys® microemulsion via the rectal mucosa.

Main Results:

• Low-dose lithium delivered via Aonys® significantly improved survival rates in prion-inoculated mice.
• This treatment regimen reduced key pathological markers, including vacuolization, astrogliosis, and neuronal loss, compared to controls.
• The protective effects of low-dose Aonys®-delivered lithium were comparable or superior to those observed with traditional high-dose lithium administration.

Conclusions:

• Lithium administered through the innovative Aonys® microemulsion system demonstrates significant therapeutic potential for prion diseases.
• This delivery method allows for effective treatment with low lithium doses, potentially avoiding chronic toxicity issues.
• The findings suggest that this lithium delivery system could be a valuable therapeutic approach for prion diseases and other neurodegenerative disorders.